Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
That's true man, there's never a bad time to take profits. Better than it turning against you and having to regret it.
I love your take on stuff. Man looking back on this trade I really took profits way to early http://investorshub.advfn.com/boards/read_msg.aspx?message_id=67348765 but a profit is a profit.
I sure wish I loaded up on DUSS a few weeks ago...
Don't you just love it when a stock starts having a predictable repeating sine wave chart pattern.
The PR released just after the bad news announced a new underwater camera. For shareholders in the red, maybe? lol
I guess there will be no more "Snapshots" at Kodak... lol!
Cliff diving anyone?
ITNS very bullish again today.
i will keep it on my watch list.
Probably not too far, unless they announce an issuance of shares to fund blah blah blah. Then you'll see it come down fast IMO.
yeah i imagine, it will be interesting where the support is on that one
$OPTR, downside OPTRtunity: http://blog.chartmystock.com/2011/09/25/optr-putshort-optrtunity.aspx
Shank's FDA profit method:
1) Buy call options and/or shares on a dip ~2 months before the date.
2) Take profits 1-2 days before the date, use some profits to buy puts.
3a) If FDA rejects, sell puts on the crash, pocketing profits again.
3b) If FDA passes, hold the puts. There's usually a price drop anyhow when longs take profits and/or the company sells shares to fund drug production and marketing.
4). Repeat on the next FDA date.
Trade safe and have fun.
-shank
FDA date watch list: http://blog.chartmystock.com/2011/09/24/f.aspx
Then again, I'm sure bong-hits in the library are prohibited... so maybe just take the movies home. lol
lol yep and yep
Thanks. Are they free to borrow? Too bad you can't bring beer and pizza to the library huh? If so I'd just camp out on the weekends with my laptop.
Great article. My public library has a movie library. They have everything from the Matrix to The Godfather.
$SLV, I've got one morrrrrre silver dollarrrrr: http://blog.chartmystock.com/2011/09/23/slv-amazing-loss-in-price.aspx
$TOFS, ain't no party like a bagholder party, y'all! : http://blog.chartmystock.com/2011/09/22/tofs-tin-foiltastic.aspx
Nice post. One of my scans yesterday was like 95% miners. Too many to chose from, so maybe this will help me cull the list down.
Gold Companies to Watch
Looking for good long term investments in gold there are some very good very knowledgeable, experienced and insightful analyst out there and Dale Mah is one of them. Any investor in gold would do well to include this in their potential investment inquiries. In this interview Dale provides a list of companies any long investor should review in depth.
a sample from the article: Agnico-Eagle Mines Ltd. - Amarillo Gold Corp. - AngloGold Ashanti Ltd. - Atacama Pacific Gold Corp. - Eco Oro Minerals Corp. - GMV Minerals Inc
http://wakingthebull.com/entry.php?1667-Gold-Companies-to-Watch-from-the-Yukon-to-Colombia
Have you tweeted your board today?
Easton Pharmaceuticals, (OTC: EAPH) a specialty pharmaceutical company that designs, develops, and markets a premium array of topically-delivered therapeutic healthcare products announced it has received and entered into discussions for two financing proposals from 2 private investment firms and accredited investors.
Easton has entered into discussions and reviewing 2 possible options available for financing. The first proposal and option presented after meetings is a conditional offer from a private investment firm and accredited investor under the condition the company first initiate the process to become a reporting issuer with the Securities and Exchange Commission. The potential investor is classified as an accredited investor based in NY State who has financed numerous public companies over the last several years. The financing is conditional and involves filing a form 10 or other type of registration statement with the SEC which entails undertaking a complete audit of its financials. Presently the company is classified as a current issuer with the OTC exchange (OTC: EAPH). The difference with being a current issuer under the present exchange is that the company presently uses a securities attorney to certify and sign off on its corporate year end and quarterly financial statements. Should the company file a form 10 and become a reporting issuer under SEC jurisdiction it would have its financial statements certified and signed off by an auditor instead of a securities attorney.
The second proposal and option presented is again from a private investment firm focused on investing in small and mid capitalized companies who is willing to finance the company via a 504 Reg D offering. Such a financing will involve the filing of a form D with the Securities and Exchange Commission with various conditions that both the company and investor must meet including investment intent by the investor. Under this option the company can raise a maximum of $1 million for every 12 month period and can be canceled at any time with no penalties or obligations.
The company is presently giving serious consideration to both proposals and options with its consultants and attorney as well as options by other firms. The 504 option is considered a quicker form of financing, but not necessarily considered a better option as only companies considered non reporting with the SEC can accept a 504 type financing and is limited to the $1 million dollar amount per 12 month period. Financing is required by the company to fulfill its corporate objectives and business plan which includes being able to market its main flagship product Viorra in various parts of the world as well as to initiate and enter into clinical North American Trials. Funding is also required for the filing of patents where the company previously advanced a retainer to a NY patent firm. Neither of the options is a guarantee that the Company will be able to close on any terms acceptable to the company but believes both are considered very good and credible. Additional details to be disclosed as they become available
About Easton Pharmaceuticals Inc
Easton Pharmaceuticals is a specialty pharmaceutical company that designs, develops, and markets a premium array of topically-delivered therapeutic healthcare products, focused on skin and circulatory conditions that impact a large and expanding number of consumers including health issues related to male and female sexual dysfunction, scar and stretch marks, cellulite and varicose veins, the world market for these conditions is in excess of $10 billion.
The company's proprietary gel formulation is an innovative and unique transdermal delivery system. Easton Pharmaceuticals' flagship product, VIORRA, is an over-the-counter aid for the treatment to restore and improve vaginal moisture and elasticity which has a very positive effect on women's sexual desire and arousal, FSAD (Female Sexual Arousal Disorder) the world market for these female conditions are in excess of $2 billion. VIORRA is a topical, daily-use product classified by the FDA as containing Generally Recognized as Safe ingredients.
For More Information Visit http://www.eastonpharma.com
Safe Harbor
This news release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (The "Act"). In particular, when used in the preceding of discussion, the words "pleased," "plan," "confident that," "believe," "expect," or "intent to" and similar conditional expressions are intended to identify forward-looking statements within the meaning of the Act and are subject to the safe harbor created by the Act. Such statements are subject to certain risks and uncertainties and actual results could differ materially from those expressed in any of the forward-looking statements. Such risks and uncertainties include, but are not limited to, market conditions, general acceptance of the company's products and technologies, competitive factors, the ability to successfully complete additional or adequate financing and other risks and uncertainties as stated in the company's financial reports and filings.
Copyright ©2011 Easton Pharmaceuticals Inc. All rights reserved. Easton Pharmaceuticals, Easton Pharma and the Easton Pharmaceuticals logo, and all other Easton Pharmaceuticals company, product, and services names and slogans are trademarks or registered trademarks of Easton Pharmaceuticals Inc.
Contacts:
Easton Pharmaceuticals Inc.
+1(416) 619-0291
+1(347) 284-0192
+1(888) 877-3723 (FAX)
Investor relations: contact@directglobalmedia.com
May I ask what browser you were using? Other people haven't had a problem. I just asked someone else to try and it worked.
Thanks for the heads up. Sometimes i put the wrong type of link on the image. Brb...
The link to the blog, or the chart link ON the blog?
Everyone had better make sure they are tweeting this board....
$TOFS, $CRWV, $YRCW... three red bags: http://blog.chartmystock.com/2011/09/20/tofs-crwv-yrcw-three-red-bags.aspx
I will, havent really looked into the chart deeply, but I do trust your intuition w chart reading. Appreciate it bud.
Just look at the daily chart before taking a position. It's trading at the top of a channel at the moment. Might want to just wait and see if it pulls back some more IMO.
yeah i dont mind being long. Thanks for the heads up Shank :). Much appreciated
It's definitely not a quick one. This might play out by Xmas or so. I could be VERY wrong though. Just doing this for fun really.
just on quick look not sure about that one. It def yo yos nicely for a trade from these levels, but prob should expect to hold for a few months. But thats strictly on a quick look and Im broke so wtf do I know.
Followers
|
12
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
270
|
Created
|
09/03/11
|
Type
|
Free
|
Moderator shankapotamus | |||
Assistants gldbggr HerrM |
Posts Today
|
0
|
Posts (Total)
|
270
|
Posters
|
|
Moderator
|
|
Assistants
|
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |